Cerebrospinal Aβ11-x and 17-x levels as indicators of mild cognitive impairment and patients’ stratification in Alzheimer’s disease

J-D Abraham1, S Prome1, N Salvetat1, L Rubrech1, S Cobò1, E du Paty1, P Galéa1, E Mathieu-Dupas1, S Ranaldi1, C Caillava2, G-A Crémer3, F Rieu1, P Robert1, F Molina1, D Laune1, F Checle2 and J Fareh1

In the present work, the concentrations of Aβ11-x and Aβ17-x peptides (x = 40 or 42), which result from the combined cleavages of β-amyloid precursor protein (AβPP) by β/α or α/γ-secretases, respectively, were assessed in cerebrospinal fluid (CSF) samples from patients with Alzheimer’s disease (AD) or mild cognitive impairment (MCI). Specific multiplexed assays were set up using new anti-40 and anti-42 monoclonal antibodies (mAbs) for the capture of these N-truncated Aβ peptides and anti-11 or anti-17 mAbs for their detection. The specificity, sensitivity and reproducibility of such assays were assessed using synthetic peptides and human cell models. Aβ11-x and Aβ17-x were then measured in CSF samples from patients with AD (n = 23), MCI (n = 23) and controls with normal cognition (n = 21). Aβ11-x levels were significantly lower in patients with MCI than in controls. Compared with the combined quantification of Aβ11-42, total Tau (T-Tau) and phosphorylated Tau (P-Tau; AlzBio3, Innogenetics), the association of Aβ11-40, Aβ17-40 and T-Tau improved the discrimination between MCI and controls. Furthermore, when patients with MCI were classified into two subgroups (MCI ≤ 1.5 or ≥ 2 based on their CDR-SB (Cognitive Dementia Rating–Sum of Boxes) score), the CSF Aβ17-40/Aβ11-40 ratio was significantly higher in patients with CDR-SB ≤ 1.5 than in controls, whereas neither Aβ11-42, T-Tau nor P-Tau allowed the detection of this subpopulation. These results need to be confirmed in a larger clinical prospective cohort.

Translational Psychiatry (2013) 3, e281; doi:10.1038/tp.2013.58; published online 16 July 2013

Introduction

Alzheimer’s disease (AD) is the most common form of dementia and is characterized by loss of memory and progressive cognitive impairment. The major histopathological hallmarks of AD are extracellular senile plaques, which mainly consist of β-amyloid peptides (Aβ),1 and intracellular neurofibrillary tangles, which are mostly composed of hyperphosphorylated microtubule-associated Tau protein.2,3 Accumulation of Aβ peptide aggregates could lead to hippocampal synaptic dysfunction,4 thereby explaining the AD memory deficits. Episodic memory loss is generally considered as the core requirement for the diagnosis of mild cognitive impairment (MCI).5,6 Early and reliable AD diagnosis at the stage of MCI would improve AD prognosis and provide the means to examine the putative efficacy of newly designed drugs as disease modifiers. Today, the combined measurement of total Tau (T-Tau), phosphorylated Tau (P-Tau) and Aβ1-42 in cerebrospinal fluid (CSF) allows the best biochemical characterization of the patients’ clinical status, even from a prognostic point of view.7–12 However, despite their good diagnostic performance, we clearly need complementary biomarkers to differentiate between AD and non-AD disorders,13–15 particularly at early stages (MCI).

In normal conditions, the β-amyloid precursor protein (AβPP) mainly undergoes a nonamyloidogenic cleavage by α-secretase activity that precludes Aβ generation.16 Conversely, in the amyloidogenic pathway, AβPP is sequentially cleaved by the β-secretase BACE1 and by the γ-secretase proteolytic complex to produce various Aβ peptides, including the full-length (fl) species Aβ1-40 and Aβ1-42.16,17 Besides flAβ peptides, many N- and C-terminally truncated variants have also been identified and isolated from cell supernatants, animal models and brain extracts from patients with AD,18–22 and they could have escaped immunodetection in the CSF because of technical limitations. This is not anecdotal as within this plethoric Aβ-linked peptidome, several Aβ truncated variants could have physiopathological and diagnostic relevance. For instance, N-truncated peptides at residue 11 of flAβ (Aβ11-x) results from BACE1-mediated β’-cleavage23 and might be seen as an indicator of β-secretase-associated AβPP processing that could happen in pathological conditions.24 Aβ17-x variants result from γ-secretase activity and could also be revelatory of a pathological situation, because γ-secretase activity is apparently downregulated in AD.25–28

Here, to evaluate Aβ11-x and Aβ17-x levels in complex fluids, including human CSF, we describe new specific multiplexed assays based on the capture of the different Aβ peptides by new specific anti-C-terminal (Cter) monoclonal antibodies (mAbs; 6H7 anti-40 antibody and 12E8 anti-42 antibody) and their detection by very specific anti-N-terminal

1SysDiag CNRS/Bio-Rad UMR3145, Montpellier, France; 2Institut de Pharmacologie Moléculaire et Cellulaire, UMR7275, team labeled by the ‘Fondation pour la Recherche Médicale’ and LABEX (Laboratory of Excellence), Valbonne, France; 3Bio-Rad Laboratories, Marnes la Coquette, France and 4CMRR, Memory Center, EA CoBTeK, University of Nice Sophia-Antipolis, Nice, France
Correspondence: Dr J-D Abraham, SysDiag CNRS/Bio-Rad UMR3145, Cap Delta Parc Euromedecine, 1682 rue de la Valsiere, Montpellier 34184, France.
E-mail: jean-daniel.abraham@sysdiag.cnrs.fr
Keywords: amyloid peptide; biomarkers; prodromal; secretase; truncated
Received 2 May 2013; accepted 25 May 2013
mAbs (7H1 anti-11 antibody and 8H5 anti-17 antibody) that were previously obtained and characterized. We then assessed the ability of these assays to monitor CSF Aβ11-34 and Aβ17-40 levels at very early AD stages and show that, unlike the currently used assays, the Aβ17-40/Aβ11-40 ratio allows discriminating between patients with very early MCI and controls. Although the number of patients was limited, our study indicates that additional N-truncated Aβ-related fragments could be used as biomarkers of AD pathology onset.

Materials and methods

Peptide synthesis. The immunogenic peptide C-KKKGS-Aβ33-42 used for the production of the anti-42 antibody included the 10 C-terminal amino acids of human Aβ starting at residue #33 (GLMVDGGVIA), referred to as Aβ33–42. The immunogenic peptide C-KKKGS-PADRE-Aβ31-40 used for anti-40 antibody production comprised the 10 C-terminal amino acids of human Aβ starting at residue #31 (IGLMVGVY), referred to as Aβ31–40. The PADRE sequence (pan HLA-DR epitope; sequence: aK(X)VAATWLKAAa, where X = L-cyclohexylalanine and a = D-amino acid) can bind to C57BL/6 mouse MHC-II molecules (H-2b haplotype) and elicit the T helper type 2 response. Additional details on their synthesis, purification and analysis are described in Supplementary Information. Both peptides were coupled via their N-terminal cysteine residue to maleimide-activated mcBSA (#77607 Pierce Conjugation Kit, Rockford, IL, USA) for immunization.

Generation of antibody-producing hybridoma clones. Experimental protocols requiring the use of mice were reviewed by the Institutional Animal Ethics Committee (Sysdiag HT-Mab facility, Montpellier, France). The detailed description of the immunization protocol, hybridoma production with the Sp2/0Ag14 myeloma cell line and mAb purification are in Supplementary Information. Clone selection (specific reactivity toward the relevant biotinylated peptide and absence of reactivity against the other biotinylated peptide) was done by sandwich enzyme-linked immunosorbent assay based on the capture of N-terminally biotinylated Aβ1-40 or Aβ1-42 (AnaSpec, Fremont, CA, USA) on streptavidin-coated plaques and their detection by hybridoma supernatants and goat anti-Fc antibodies (Sigma, St Louis, MO, USA). Specific anti-40 (6H7 clone) and anti-42 (12E8 clone) antibodies were selected, amplified and purified on protein A Sepharose columns (GE Healthcare, Piscataway, NJ, USA).

X-MAP assays. All Aβ peptides were purchased from AnaSpec as lyophilized powder, solubilized in dimethyl sulfoxide (2 mg ml\(^{-1}\)) and conserved at −20 °C. Standard aliquots (2 µg ml\(^{-1}\) in dimethyl sulfoxide) were prepared and stored at −20 °C. For test reproducibility, a new aliquot was used for each experiment and was not kept after standard reconstitution in Dulbecco’s modified Eagle’s medium/1% foetal calf serum.

Different multiplexed Cter assays, which allow the capture of peptides via their C-terminus, were designed to measure the concentration of truncated Aβ peptides. Carboxylated magnetic beads from different microsphere numbers were chemically coupled with anti-40 6H7, anti-42 12E8 or IRR (irrelevant) antibodies and coupling evaluated with phycoerythrin-coupled goat anti-mouse IgGs (Jackson Immunoresearch, Suffolk, UK). For truncated peptide detection, the anti-11 7H1 and anti-17 8H5 mAbs were used as detection antibodies after biotinylation (EZ-link Micro Biotinylation Kit, Pierce). Two different Cter sandwich assays were designed, based on the same bead combination (the 6H7/12E8/IRR triplex), to detect either 11-x or 17-x species (X = 40 or 42) depending on the used detection antibody.

CSF Aβ11-42, T-Tau and P-Tau concentrations were measured with the AlzBio3 multiplex assay (Innotest, Innogenetics, Gent, Belgium).

CSF samples. Human CSF samples from age-matched patients with AD (n = 23) or MCI (n = 23) and donors with normal cognition (controls, n = 21) were provided by PrecisionMed (San Diego, CA, USA). The clinical protocol, consent forms and CSF registry were approved by the Western Institutional Review Board located in Washington, USA. Subjects with Mini-Mental State Examination (MMSE) score >13 to <28 signed the approved written informed consent and agreed to blood sampling by venipuncture (<90 ml blood) and CSF collection (<25 ml) by lumbar puncture every 6 months. The age at enrolment was >50 years and previous (within 2 years) brain scans excluded other pathologies as cause of dementia/memory disorder. Exclusion criteria were (1) evidence of multi-infarct dementia and drug intoxication, thyroid disease, pernicious anaemia, tertiary syphilis, chronic infections of the nervous system, normal pressure hydrocephalus, Huntington’s disease, Creutzfeldt–Jakob disease, brain tumours, polypharmacy and Korsakoff’s syndrome; (2) life expectancy <3 years; and (3) any contraindication to lumbar puncture, including anticoagulant therapy and subjects taking aspirin, aspirin-containing products or non-steroidal anti-inflammatory products, within 1 week from lumbar puncture. The probable AD classification was based on the NINCDS-ADRDA criteria: MMSE ≥13 and ≤26; deficit in two or more areas of cognition; no consciousness disturbance; onset between 40 and 90 years, generally after the age of 65; and absence of systemic disorders or other brain disease that could account for the cognitive impairment. MCI was diagnosed based on: MMSE ≥21 and ≤28; no dementia; memory complaint; preserved general cognitive function; intact daily living activities; problems with two or less of the following activities: phone calls, meal preparation, handling money, completing chores; abnormal memory function documented by scores below the education-adjusted cutoff at the logical Memory II subscale (delayed paragraph recall) from the Wechsler Memory Scale–Revised (maximum score = 25). The ADAS-Cog and Cognitive Dementia Rating–Global Score (CDR-GS) scores were calculated for each participant. MMSE, ADAS-Cog and CDR sum of boxes (CDR-SB) significantly discriminated the different groups with no gender-linked differences (Table 1a). Patients with MCI were divided as indicated in the validated interpretative guideline for the CDR-SB score, with a lower cutoff (1.5 instead of 2) for the detection of very early cognitive impairment. MCI patients with CDR-SB ≤1.5 (MCI ≤1.5 group, n = 9) correspond to patients with ‘questionable impairment’ and the MCI ≥2
### Table 1 Demographic data and psychometric assessment of the patients

|                      | CTRL (n = 21) | MCI (n = 23) | AD (n = 23) | P-value          |
|----------------------|---------------|--------------|-------------|------------------|
| CDR-GS 0             | n = 21        | n = 1        | n = 7       |                  |
| CDR-GS 0.5           |               |              |             |                  |
| CDR-GS 1             |               |              |             |                  |
| CDR-GS 2             |               |              |             |                  |
| MMSE                 | 29.71 ± 0.46  | 24.78 ± 2.13 | 17.57 ± 2.86 | < 0.0001        |
|                      | (29–30)       | (21–28)      | (13–24)     |                  |
| ADAS-cog             | 0             | 18.04 ± 8.04 | 36.91 ± 11.02 | < 0.0001        |
|                      |              | (2–36)       | (22–59)     |                  |
| CDR-SB               | 0             | 2.3 ± 1.35   | 6.5 ± 3.81  | < 0.0001        |
|                      | (0–5.5)       | (2–14)       |             |                  |
| Mean age, year       | 65.48 ± 5.31  | 69.57 ± 9.52 | 77.39 ± 6.83 | 0.084           |
|                      | (60–77)       | (50–82)      | (66–90)     |                  |
| Sex, female/male     | 10/11         | 10/13        | 15/8        | 0.55             |
| (%)                  | (47.62/52.38) | (43.48/56.52)| (65.22/34.78)|                  |

|                      | CTRL (n = 21) | MCI < 1.5 (n = 9) | MCI ≥ 2 (n = 14) | P-value          |
|----------------------|---------------|-------------------|------------------|------------------|
| MMSE                 | 29.71 ± 0.46  | 25.89 ± 1.83      | 24.07 ± 2.06     | < 0.0001        |
|                      | (29–30)       | (23–28)           | (21–28)          |                  |
| ADAS-cog             | 0             | 16 ± 7.67        | 19.36 ± 8.27     | < 0.0001        |
|                      |              | (2–27)           | (7–36)           |                  |
| CDR-SB               | 0             | 1 ± 0.5          | 3.14 ± 1        | < 0.0001        |
|                      |              | (0–1.5)          | (2–5.5)          |                  |
| Age, year            | 65.48 ± 5.31  | 70.44 ± 7.94     | 69 ± 10.67       | 0.053           |
|                      | (60–77)       | (58–81)          | (50–82)          |                  |
| Sex, female/male     | 10/11         | 4/5              | 6/8              | 0.88             |
| (%)                  | (47.62/52.38) | (44.45/56.5)     | (42.85/72.5)     | 0.94             |

Abbreviations: AD, Alzheimer’s disease; ADAS-cog, Alzheimer’s Disease Assessment Scale–Cognitive Subscale; CDR-GS, Cognitive Dementia Rating–Global Score; CDR-SB, Cognitive Dementia Rating–Sum of Boxes; CTRL, controls; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination.

Statistical analyses. Statistical analyses and figures were done using the ‘R/Bioconductor’ statistical open source software or the SAS software v9.2 (SAS Institute, Cary, NC, USA). Univariate differential analysis was performed with the more appropriate statistical test (control of the normality and homoscedasticity hypotheses). Multiple testing corrections enabled to adjust the P-value of each marker to control the false discovery rate. The Benjamini and Hochberg approach was applied with the ‘multi-test’ package. Adjusted P-values < 0.05 were considered as statistically significant. All biomarker distributions are illustrated with boxplots and medians. The accuracy of each marker and its discriminatory power was evaluated using the Receiving Operating Characteristics (ROC) analysis. ROC curves are the graphical visualization of the reciprocal relation between sensitivity (Se) and specificity (Sp) of a test for various values. In addition to univariate analysis, all markers were combined to evaluate the potential increase in sensibility and specificity using two multivariable approaches (logistic regression and mROC method). A logistic regression model was applied using biomarkers as categorical variables and the median values as cut-points. A backward selection process was considered in order to converge on the best multivariate model. The Wald statistic criterion of P-value < 0.05 was used to keep variables in the final statistical model. Adjusted odds ratios and their 95% confidence intervals were computed for significant variables in the final model. The mROC program is dedicated to identifying the linear combination that maximizes the area under the ROC curve. The equation for the underlying combination is provided and can be used as a decision rule. The DeLong’s test was also employed to compare several ROC curves.

Results

Antibody characterization. We produced specific anti-40 (6H7) and anti-42 (12E8) mAbs that displayed high affinity toward their corresponding synthetic peptides and exclusive specificity as no significant crossreaction toward other C-terminal truncated Aβ peptides was observed by surface plasmon resonance analyses (Supplementary Table S1). Thus, unlike 4G8 that, as expected, interacted similarly with both N-40 and N-42 peptides with affinities in the nanomolar range, 6H7 only bound to N-40 peptides, whereas 12E8...
interacted with all tested N-42 peptides with high affinity. Surface-enhanced laser desorption/ionization analysis confirmed that 6H7 and 12E8 bound specifically to Aβ11-x and Aβ17-x peptides, respectively, without any crossreactivity toward other Aβ peptides (Supplementary Figure S1).

Characterization and validation of the 6H7/12E8/IRR triplex assays. We then developed two 6H7/12E8/IRR triplex assays in which Aβ11-40 and Aβ14-42 peptides are simultaneously captured via their C-terminus by the 6H7 and 12E8 antibodies. Aβ11-x or Aβ17-x peptides are then detected with the 7H1 or 8H5 mAbs that were previously characterized. Sandwich assays performed with all mAb combinations showed a detection limit of <10 pg ml\(^{-1}\) (Supplementary Figure S2). This rather high sensitivity allowed the accurate assessment of Aβ11-x peptides in complex media. The reproducibility of these assays was examined using supernatants from HEK293 cell lines that express wild-type APP, APPwt, wild-type APP and BACE1 (APPwt + BACE1) or APP with the Swedish mutation (APPsw) and that secrete various Aβ11-x and Aβ17-x cells that secrete high amounts of Aβ11-x and Aβ11-x peptides, 24 the 6H7 and 12E8 antibodies captured only Aβ11-40 and Aβ11-42 and Aβ11-42 peptides, respectively, without any crossreactivity toward other Aβ peptides (Supplementary Figure S1).

**Table 2a** Concentration of the different AD biomarkers and of N-truncated Aβ peptides in controls (CTRL) and patients with MCI or AD, and their significance in differentiating the three study groups.

| Mean (pg ml\(^{-1}\)) ± s.d. (min–max) | P-value |
|--------------------------------------|---------|
| **CTRL (n = 21)**                   | **MCI (n = 23)** | **AD (n = 23)** | **CTRL vs MCI** | **CTRL vs AD** | **MCI vs AD** |
| Aβ11-42                             | 557.48 ± 88.45 | 468.20 ± 152.09 | 356.20 ± 107.48 | <0.05          | <0.001         | <0.01         |
| (380.21–699.62)                     | (179.41–829.88) | (166.35–588.39) | (34.29–398.56)  |                |                |               |
| T-Tau                               | 54.72 ± 20.13  | 79.51 ± 37.90   | 145.40 ± 89.10  | <0.05          | <0.001         | <0.01         |
| (22.75–100.22)                      | (29.95–174.34) | (34.29–398.56)  |                |                |                |               |
| P-Tau                               | 27.61 ± 7.21  | 36.85 ± 16.99   | 56.37 ± 35.65   | <0.05          | <0.001         | <0.01         |
| (15.27–41.10)                       | (12.59–78.16)  | (13.75–171.99)  |                |                |                |               |
| Aβ11-40                             | 163.56 ± 39.35 | 133.10 ± 28.76  | 133.69 ± 56.77  | <0.01          | 0.051          | 0.97          |
| (95.76–230.23)                      | (85.34–192.69) | (30.77–255.56)  |                |                |                |               |
| Aβ11-42                             | 26.63 ± 7.14  | 22.23 ± 7.01    | 23.70 ± 11.30   | <0.01          | 0.32           | 0.60          |
| (15.67–40.99)                       | (13.81–43.87)  | (5.02–50.02)    |                |                |                |               |
| Aβ17-40                             | 43.34 ± 28.36 | 45.58 ± 25.49   | 33.93 ± 20.40   | 0.09           | 0.72           | 0.09          |
| (9.85–98.65)                        | (8.81–100.02)  | (5.19–66.03)    |                |                |                |               |
| Aβ17-42                             | 11.63 ± 3.92  | 11.51 ± 7.12    | 8.15 ± 3.60     | 0.94           | <0.05          | 0.051         |
| (5.58–18.80)                        | (3.92–27.34)   | (1.35–15.25)    |                |                |                |               |

**Abbreviations:** AD, Alzheimer’s disease; CTRL, controls; MCI, mild cognitive impairment; P-Tau, phosphorylated Tau; T-Tau, total Tau. The CSF biomarkers presented classical AD-like profiles with significant progressive decrease of Aβ11-40 and increase of both T-Tau and P-Tau concentration in accordance with the severity of the pathology. The concentration of the Aβ11-40 and Aβ11-42 peptides was lower in patients with MCI than in controls. Aβ17-42 level did not differ significantly in the three groups and Aβ17-42 concentration was lower in the AD group.

**Table 2b** Diagnostic potential (mROC) of the different CSF biomarkers as univariate variables for MCI diagnosis.

| CTRL vs MCI | Aβ11-42 | T-Tau | P-Tau | Aβ11-40 | Aβ11-42 | Aβ17-40 | Aβ17-42 |
|-------------|---------|-------|-------|---------|---------|---------|---------|
| Median (pg ml\(^{-1}\)) | 535.14  | 56.6  | 27.47 | 147.58  | 22.21  | 37.85  | 11.15   |
| Cutoff (pg ml\(^{-1}\)) | 490.47  | 64.16 | 27.26 | 146.66  | 21.87  | 46.15  | 11.05   |
| Sensitivity (%) | 60.87  | 60.87 | 69.57 | 69.57   | 65.22  | 52.17  | 60.78   |
| Specificity (%) | 76.19  | 76.19 | 66.67 | 71.43   | 67.19  | 66.67  | 61.19   |
| NPV (%) | 64.00  | 64.00 | 66.67 | 68.18   | 66.67  | 65.00  | 59.09   |
| PPV (%) | 73.68  | 73.68 | 69.57 | 72.73   | 75.00  | 63.16  | 63.64   |
| AUC | 0.704  | 0.706 | 0.684 | 0.739   | 0.708  | 0.537  | 0.594   |
| 95% Confidence interval | (0.548–0.861) | (0.548–0.864) | (0.522–0.847) | (0.588–0.890) | (0.548–0.868) | (0.360–0.715) | (0.419–0.769) |
| P-value (DeLong’s test) | 0.021  | 0.019 | 0.036 | 0.006   | 0.018  | 0.672  | 0.285   |

**Abbreviations:** AUC, area under the curve; CSF, cerebrospinal fluid; CTRL, controls; MCI, mild cognitive impairment; NPV, negative predictive value; PPV, positive predictive value; P-Tau, phosphorylated Tau; T-Tau, total Tau.

The cut-offs were chosen to yield the highest Youden’s index. P-values (DeLong’s test) represent the comparison of biomarkers with AUC = 0.5.

**Table 3** Diagnostic potential (mROC) of the different CSF biomarkers as multivariate variables for MCI diagnosis.

| CTRL vs MCI | T-Tau + P-Tau | T-Tau + Aβ11-40 | T-Tau + Aβ17-40 |
|-------------|---------------|-----------------|-----------------|
| Cutoff      | −0.79         | −1.28           | −1.28           |
| Sensitivity (%) | 60.87       | 73.91           | 73.91           |
| Specificity (%) | 66.67       | 95.24           | 95.24           |
| NPV (%) | 60.87         | 76.92           | 76.92           |
| PPV (%) | 66.67         | 94.44           | 94.44           |
| AUC | 0.727         | 0.89            | 0.89            |
| 95% Confidence interval | (0.575–0.878) | (0.791–0.990) | (0.791–0.990) |
| P-value (DeLong’s test) | 0.01         | <0.0001         | <0.0001         |

**Abbreviations:** AUC, area under the curve; CSF, cerebrospinal fluid; CTRL, controls; MCI, mild cognitive impairment; NPV, negative predictive value; PPV, positive predictive value; P-Tau, phosphorylated Tau; T-Tau, total Tau.

The cutoffs were chosen to yield the highest Youden’s index. P-values (DeLong’s test) represent the comparison of biomarkers with AUC = 0.5.
peptides as well as in human control CSF samples (Supplementary Figure S3). Reproducibility was satisfactory for CSF Aβ11-x measurements (percent coefficient of variation <20%), and slightly more variable but still acceptable for Aβ17-x measurements (percent coefficient of variation between 20 and 30% for Aβ17-40 and ~30% for Aβ17-42).

To further validate the assay specificity, we examined the ability of the multiplexed assays to discriminate between peptides differing by only one amino acid. Thus, we compared the reactivity of the 6H7/7H1 and 6H7/4G8 sandwich assays toward Aβ 9–40, 10–40, 11–40, 12–40 or 13–40 peptides (Supplementary Figure S4A) and the reactivity of the 6H7/8H5 and 6H7/4G8 sandwich assays toward Aβ 15–40, 16–40, 17–40, 18–40 or 19–40 peptides (Supplementary Figure S4B). The 6H7/7H1 and 6H7/8H5 assays clearly showed a restricted specificity toward Aβ11-40 and Aβ17-40 peptides, respectively. Conversely, the 4G8 antibody detected all tested peptides with different sensitivities, according to the peptide sequence.

As the concentrations of truncated fragments and flAβ in pathological conditions are unknown and could vary during the disease course, we examined whether high levels of flAβ could influence the detection of truncated fragments in the two assays. High concentrations of Aβ1-40 or Aβ1-42 (>100-fold above the affinity constant for the truncated fragments) did not significantly affect Aβ11-x or Aβ17-x detection, respectively (Supplementary Figure S5). We therefore conclude that, in these experimental conditions, the binding capacity of the beads remains sufficient to preclude any technical bias, thereby validating the use of the 6H7/12E8/IRR triplex assays for the detection and quantification of N-truncated Aβ peptides in human CSF samples.

Table 4 Logistic regression coefficient and odds ratios of the best multivariate model (controls vs MCI patients)

| Effect                | Estimate | P-value | Odds ratio | 95% CI          |
|-----------------------|----------|---------|------------|-----------------|
| Intercept             | 0.49     | 0.45    | 0.17       | (0.035–0.85)    |
| Tau                   | 0.75     | 0.03    | 18.81      | (2.84–124.58)   |
| Aβ11-40               | 2.94     | 0.002   | 18.81      | (2.84–124.58)   |
| Aβ17-40               | 1.89     | 0.038   | 0.15       | (0.025–0.90)    |
| Intercept             | 1.224    | 0.016   | 15.30      | (3.51–66.70)    |
| T-Tau + Aβ11-40 + Aβ17-40 | 2.73 | 0.0003 | 15.30      | (3.51–66.70)    |

Abbreviations: CI, confidence interval; MCI, mild cognitive impairment; T-Tau, total Tau.

Figure 1 The Aβ1–42/P-Tau and Aβ1–42/T-Tau ratios do not allow discriminating between the mild cognitive impairment (MCI) ≤1.5 group and controls (CTRL). P-Tau, phosphorylated Tau; T-Tau, total Tau. The Aβ17-40/Aβ11-40 ratio significantly differentiates the MCI ≤1.5 group from controls. The symbol ‘-’ indicates P > 0.05; ‘*’ P < 0.05; ‘**’ P < 0.01.
Quantification of Aβ11-x and Aβ17-x peptides for MCI diagnosis

J-D Abraham et al

N-truncated Aβ peptides for MCI diagnosis

Translational Psychiatry

6

Quantification of Aβ11-x and Aβ17-x peptides in CSF allows MCI detection at early stages. We then quantified the concentration of Aβ11-40, Aβ11-42, Aβ17-40 and Aβ17-42 peptides using the two Cter 6H7/12E8/IRR triplex assays and the concentration of Aβ1-42, T-Tau and P-Tau with the AlzBio3 assay in CSF samples from patients with AD or MCI (n=23 per group) and controls (n=21; Table 2a). As previously reported,10,47 Aβ1-42 was significantly reduced whereas T-Tau and P-Tau concentrations were significantly higher in CSF samples from patients with MCI than from controls (P<0.05). These differences were further exacerbated at the AD stage (P<0.001). Aβ11-40 and Aβ11-42 concentrations were significantly lower in patients with MCI than in controls (P<0.01), whereas no significant difference was observed in Aβ17-x levels in the three groups, but for Aβ17-42 between controls and AD (P<0.05). Aβ11-40 and Aβ11-42 peptides discriminated more efficiently patients with MCI from controls, even when compared with the classical biomarkers Aβ1-42, T-Tau and P-Tau (Table 2b). Analysis of different marker combinations for discriminating patients with MCI from controls using the mROC program (Table 3) and logistic regression analysis (Table 4) indicated that the combination of Aβ11-40, Aβ17-40 and T-Tau allowed the best evaluation of the MCI risk (multivariate adjusted odds ratio: 15.30, P<0.05 for each biomarker). Accordingly, a person with a CSF Aβ11-40 level <147.6 pg ml⁻¹ was 18.8 times more at risk to have MCI. This result was strengthened by the mROC approach, which confirmed that, compared with the reference Aβ1-42, T-Tau and P-Tau combination (sensitivity 60.87%; specificity 66.67%; area under the ROC curve 0.727), the Aβ11-40, Aβ17-40 and T-Tau combination better discriminated patients with MCI from controls (sensitivity 73.91%; specificity 95.24%; area under the ROC curve 0.890; Table 3 and Supplementary Figure S6).

Discussion

This study highlights for the first time the potential diagnostic value of the CSF concentration of Aβ11-40, Aβ11-42, Aβ17-40 and Aβ17-42 peptides for early AD detection and MCI characterization. These results are based on new sensitive multiplexed assays that were validated using different synthetic peptides and cell supernatants, before use in human CSF samples. We also show that the Aβ11-40, Aβ17-40 and T-Tau combination might better discriminate patients with MCI from controls than the currently used Aβ1-42, T-Tau and P-Tau combination.

The results obtained with these multiplexed assays in controls and patients with MCI or AD highlight several important points. First, the Aβ1N-40 and Aβ1N-42 diagnostic performances in controls and patients with MCI are not significantly different. This suggests that the subsequent cleavages of β'-secretase (C89) and α-secretase (C83)-derived Aβ1PP fragments by γ-secretase leading to Aβ11-x or Aβ17-x peptides, respectively, does not account for the setting of early proteolytic alterations responsible for the generation of N-terminally truncated Aβ fragments during early MCI stages.

Second, the Aβ11-40 levels in CSF samples from MCI patients were lower than in controls. Several previous studies demonstrated that BACE1 β'-cleavage between the Y10 and E11 residues of Aβ is dependent on the BACE1 activity level. Aβ11-x concentration is supposed to be lower in physiological conditions than in AD because BACE1 is upregulated in AD-affected brains, and could be associated with hippocampal atrophy.57 The apparent CSF reduction of Aβ11-x peptides in MCI could reflect their high hydrophobicity and aggregative properties, thus explaining their presence in plaques and their reduced presence in CSF samples as previously described for pathogenic flAβ42. Alternatively, one cannot exclude the possibility of a modification of BACE1 activity/affinity toward other cleavage sites as previously suggested that would favour breakdown at the β'-site cleavage rather than at the β one. A proteolytic shift between β and β' sites of cleavages was recently highlighted by the discovery of a new Aβ1PP mutation at the E11 residue (E682K) in a Belgian patient with early-onset AD. This mutation prevents β'-cleavage and thus simultaneously decreases the production of C89 fragments and Aβ11-x peptides, while increasing that of C99 fragments and Aβ1-x peptides.61 This finding suggests that elevated Aβ11-x concentration in CSF samples represents a protective signature because Aβ1PP cleavage at the β'-site has been considered nonamyloidogenic.61 It would be interesting to evaluate the CSF concentration of Aβ11-x in these patients and in patients with other APP mutations, such as the A673T mutation that has protective effect against AD by affecting directly the β'-cleavage of Aβ1PP by BACE1 and reducing Aβ1-x secretion.62
Third, Aβ{17-x} measurements, especially Aβ{17-40}, are of interest for discriminating between controls and patients with MCI, as shown by the mROC and logistic regression analyses. This may be explained by the heterogeneity of the MCI group. Indeed, this population could be divided in two subgroups (MCI ≤ 1.5 and MCI > 2, based on their CDR-SB score). In our study, despite the low number of patients, the CDR-SB classification fitted very well with the scores of other cognitive tests, such as the MMSE or ADAS-cog (see Table 1b), thus strengthening our results. The Aβ{1-42}, T-Tau and P-Tau biomarkers and the Aβ{1-42}/T-Tau and Aβ{1-42}/P-Tau ratios, which were reported to have prognostic values,10,11,63–66 could not discriminate controls from the MCI ≤ 1.5 group. Conversely, the Aβ{17-40}/Aβ{11-40} ratio was significantly higher in the MCI ≤ 1.5 group than in controls. Despite a lower discriminating value, the Aβ{17-40} detects the CSF concentrations of secreted APP very first steps of AD. Indeed, previous studies aimed at investigating a possible role of Aβ{17-40} in the progression and suggest the possible role of Aβ{17-40} as new biomarkers for improving MCI detection and characterization and as a consequence the stratification of MCI patients has to be further validated in longitudinal clinical studies, especially for delineating the outcome of the different MCI subpopulations. Our study adds new candidates to the cohort of Aβ-related fragments that could contribute to the aetiology of early-stage AD. Overall, it indicates that conclusions based on the monitoring of flAβ alone or on the results of immunological assays using antibodies that interact nonspecifically with all Aβ{N-40/42} species should be reconsidered.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements. We thank Dominique Piquer, Audrey Malet, Julien Balicchi, Julia Mathieu, Isabelle Garric and Elisabeth Billy for their excellent technical assistance. The research leading to these results has received grants from the Agence Nationale de la Recherche (ANR-MNP Alzamyd) via the French Plan Alzheimer 2008–2012 and Eurobiomed funding, SR and CC are supported by the ANR-MNP Alzamyd grant. SystDiag high-throughput monoclonal antibody facility (HT-Mab) received grants from the Languedoc-Roussillon region via IBISA funding. FC is supported through the LABEL (excellence laboratory, program investment for the future) DISTAL2 (Development of Innovative Strategies for a Transdisciplinary approach to ALzheimers’s disease) and is recipient of a Hospital Contract for Translational Research (CHRT) between INSERM and the CHU of Nice.

1. Sekoe DJ, Podilsy MB, Joachim CL, Vickers EA, Lee G, Fritz LC et al. Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneuronal tissues. Proc Natl Acad Sci USA 1988; 85: 7341–7345.
2. Kish K, Joachim CL, Sekoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 1988; 85: 4044–4048.
3. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 319–340.
4. Sims NR, Bowen DM, Allen SJ, Smith CC, Neary D, Thomas DJ et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem 1983; 40: 503–509.
5. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HM, Fox NC et al. The diagnosis of mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303–308.
6. Vanderstichele H, De Vrese K, Blennow K, Andreassen N, Sindou C, Ivanou A et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU11F assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies. Clin Chem Lab Med 2006; 44: 1472–1480.
7. Albert MS, Vanderstichele H, De Meyer G, Wallin A, Holmberg B et al. Simultaneous measurement of beta-amyloid{1-42}, total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336–345.
8. Buchhave P, Blennow K, Zetterberg H, Stornrud E, Londos E, Andreassen N et al. Longitudinal study of CSF biomarkers in patients with Alzheimer’s disease. PLoC One 2009; 4: e6294.
9. Mattsson N, Zetterberg H, Hansson O, Andreassen N, Parnetti L, Jonsson M et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385–393.
10. Shaw LM, Vanderstichele H, Knaps-Czajka M, Clark CM, Aisen PS, Petersen RC et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403–413.
11. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U et al. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a simultaneous mono-center population. J Alzheimers Dis 2011; 24: 537–546.
12. Schoenbroemn NS, Reesink FR, Venwey NA, Kester ML, Teunisse CG, van den Ven PM et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78: 47–54.
13. Abraham JD, Calvayrac-Pawlowski S, Cobo S, Salvetat N, Vicat G, Molina L et al. Measurement of PEPF, nephrilagin and tau in cerebrospinal fluid improves the diagnostic discrimination between Alzheimer’s disease and other dementias. Biomarkers 2011; 16: 161–171.
14. de Souza LC, Laman F, Bellard S, Jardel C, Houillier C, De Paz R et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer’s disease from other cortical dementias. J Neurol Neurosurg Psychiatry 2011; 82: 240–246.
15. Checier F. Processing of the beta-amyloid precursor protein and its regulation in Alzheimer’s disease. J Neurochem 1995; 65: 1431–1444.
16. Zhang H, Ma O, Zhang YW, Xu H. Proteolytic processing of Alzheimer’s beta-amyloid precursor protein. J Neurochem 2012; 120(Suppl 1): 9–21.
17. Saido TC, Iwashutu T, Mann DM, Shimada H, Ibara Y, Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(b)E, in senile plaques. Neuron 1995; 14: 457–466.
18. Saido TC, Yamao-Harigaya W, Iwashuto T, Kawashima S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 1996; 219: 173–176.
19. Sergeant N, Bemois S, Ghestem A, Droboeck H, Kostanjsevicki V, Missiaen C et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer’s disease as new targets for the vaccination approach. J Neurochem 2003; 85: 1581–1591.
20. Portelius E, Tran AJ, Andreassen U, Persson R, Brinkmalm G, Zetterberg H et al. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 2008; 7: 4433–4439.
21. Sevalle J, Amoyel A, Robert P, Fournie-Zaluski MC, Roques B, Checier F. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem 2009; 109: 248–256.
22. Liu K, Doms RW, Lee VM. Gu11 site cleavage and N-terminally truncated A beta protein production upon BACE overexpression. Biochemistry 2002; 41: 3128–3136.
23. Ranaldi S, Caillava C, Prome S, Rubrecht L, Cobo S, Salvetat N et al. N-truncated Abeta peptides in complex fluids unraveled by new specific immunoassays. J Neurochem 2012; 124(4): 457–466.
